CompletedNot Applicable

The STAR Prospective Clinical Series

United States50 participantsStarted 2013-06

Plain-language summary

Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. Exclusion Criteria: * The device is contraindicated in subjects with heart pacemakers, or other electronic device implants. * The device is contraindicated in vertebral body levels C1-7.

What they're measuring

Change in Pain

Timeframe: 1 month

Trial details

NCT IDNCT02217150

SponsorDFINE Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2014-12

View on ClinicalTrials.gov More Metastasis to Vertebral Column trials